Doses and methods for administering telavancin or a pharmaceutically-acceptable salt thereof to a human patient having an infection caused by Staphylococcus aureus, such as bacteremia, pneumonia, endocarditis, osteomyelitis, a prosthetic joint infection or a complicated skin and skin structure infection, are disclosed. Also disclosed are methods for treating an infection caused by Staphylococcus aureus in a human patient using telavancin or a pharmaceutically-acceptable salt thereof. The dose of telavancin administered to the patient is determined, in part, by the weight and creatinine clearance of the patient.本發明揭示向人類患者投予特拉萬星(telavancin)或其醫藥學上可接受之鹽之劑量及方法，該人類患者具有由金黃色葡萄球菌(Staphylococcus aureus)引起之感染，諸如菌血症、肺炎、心內膜炎、骨髓炎、人工關節感染或複雜的皮膚及皮膚結構感染。亦揭示使用特拉萬星或其醫藥學上可接受之鹽治療人類患者中之由金黃色葡萄球菌引起之感染的方法。投予至該患者之特拉萬星之劑量部分地由該患者之重量及肌酐清除率確定。
